Replies to post #204 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

>Do we infer that the selection of Dr. Mayers, who specializes in HIV, that IDIX wants to put more focus on gearing up their HIV clinical trials?<

That’s a reasonable inference, IMO. The HBV and HCV programs are run by a joint committee of NVS and IDIX, but the HIV program is managed entirely by IDIX (until such time that NVS might want to license it).

In spite of the above, I’m inclined to view the CMO change as more negative than positive. I like the companies I invest in to have a core management team that is very stable. (GTCB is a case in point.)